All In Biotech

Drug Trial Radar · NCT04767373

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants

Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,632 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,632

Actual

Start

Apr 7, 2021

Primary completion

Jul 9, 2024

Study completion Jul 9, 2024

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, up to 1 year
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study are to evaluate the efficacy and safety of clesrovimab in healthy pre-term and full-term infants. It is hypothesized that clesrovimab will reduce the incidence of respiratory syncytial virus (RSV)-associated medically attended lower respiratory infection (MALRI) from Days 1 through 150 postdose compared to placebo.

Conditions

  • Respiratory Syncytial Virus Infection

Interventions

  • ClesrovimabBiological

    Clesrovimab solution

  • PlaceboDrug

    Placebo (0.9% sodium chloride \[NaCL\]) solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RSV Season 1: Number of Participants With Respiratory Syncytial Virus (RSV)-Associated Medically Attended Lower Respiratory Infection (MALRI)Time frame: From Day 1 (postdose) to Day 150
  2. RSV Season 1: Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)Time frame: From Day 1 (postdose) to Day 5
  3. RSV Season 1: Percentage of Participants With FeverTime frame: From Day 1 (postdose) to Day 5
  4. RSV Season 1: Percentage of Participants With Solicited Systemic AEsTime frame: From Day 1 (postdose) to Day 5
  5. RSV Season 1: Percentage of Participants With Anaphylaxis/Hypersensitivity AE of Special Interest (AESI)Time frame: From Day 1 (postdose) to Day 42
  6. RSV Season 1: Percentage of Participants With Rash AESITime frame: From Day 1 (postdose) to Day 42
  7. RSV Season 1: Percentage of Participants With ≥1 Nonserious AETime frame: From Day 1 (postdose) to Day 42
  8. Percentage of Participants With Serious Adverse Events (SAEs)Time frame: RSV Season 1: Day 1 to Day 365, RSV Season 2: Day 366 to Day 515

Locations

217 sites in 24 countries. Site status is shown where the registry gives one.

  • Southeastern Pediatric Associates, P.A. ( Site 0008)

    Dothan, Alabama

  • Northwest Arkansas Pediatric Clinic ( Site 0050)

    Fayetteville, Arkansas

  • Children's Clinic of Jonesboro, PA ( Site 0058)

    Jonesboro, Arkansas

  • Long Beach Memorial Medical Center ( Site 0014)

    Long Beach, California

  • Madera Family Medical Group ( Site 0046)

    Madera, California

  • Orange County Research Institute ( Site 0057)

    Ontario, California

  • Children's Hospital Colorado ( Site 0066)

    Aurora, Colorado

  • Optumcare Colorado Springs, LLC ( Site 0022)

    Colorado Springs, Colorado

  • Children's National Hospital ( Site 0076)

    Washington D.C., District of Columbia

  • MedStar Georgetown Pediatrics ( Site 0047)

    Washington D.C., District of Columbia

  • Next Phase Research Alliance, LLC ( Site 0071)

    Homestead, Florida

  • Acevedo Clinical Research Associates ( Site 0002)

    Miami, Florida

  • Tekton Research ( Site 0080)

    Chamblee, Georgia

  • Meridian Clinical Research, LLC ( Site 0083)

    Macon, Georgia

  • Clinical Research Prime ( Site 0075)

    Idaho Falls, Idaho

  • Saltzer Medical Group ( Site 0004)

    Nampa, Idaho

  • Cotton-O'Neil Clinical Research Center PediatricCare ( Site 0061)

    Topeka, Kansas

  • ACC Pediatric Research ( Site 0067)

    Haughton, Louisiana

  • Meridian Clinical Research, LLC ( Site 0082)

    Hastings, Nebraska

  • Midwest Children's Health Research Institute, LLC ( Site 0044)

    Lincoln, Nebraska

  • Dartmouth-Hitchcock Medical Center ( Site 0031)

    Lebanon, New Hampshire

  • Rutgers University-Pediatric Clinical Research Center ( Site 0055)

    New Brunswick, New Jersey

  • Javara - Wake Forest Health Network - Ford, Simpson, Lively & Rice Pediatrics ( Site 0093)

    Winston-Salem, North Carolina

  • Senders Pediatrics ( Site 0062)

    Cleveland, Ohio

  • Ohio Pediatric Research Association ( Site 0063)

    Dayton, Ohio

  • CCP- Kid's Way ( Site 0017)

    Hermitage, Pennsylvania

  • UPMC Children's Hospital of Pittsburgh - Primary Care Center - Oakland ( Site 0043)

    Pittsburgh, Pennsylvania

  • Coastal Pediatric Research ( Site 0013)

    Charleston, South Carolina

  • Tribe Clinical Research, LLC ( Site 0015)

    Greenville, South Carolina

  • Holston Medical Group ( Site 0040)

    Kingsport, Tennessee

  • Javara - Privia Medical Group North Texas - Frisco ( Site 0086)

    Frisco, Texas

  • University of Texas Medical Branch at Galveston ( Site 0059)

    Galveston, Texas

  • DM Clinical Research ( Site 0005)

    Houston, Texas

  • FMC Science - Lampasas ( Site 0011)

    Lampasas, Texas

  • DCOL Center for Clinical Research ( Site 0042)

    Longview, Texas

  • University Health System- San Antonio ( Site 0048)

    San Antonio, Texas

  • Private Practice - Dr. Etokhana ( Site 0089)

    San Antonio, Texas

  • Road Runner Research, Ltd ( Site 0049)

    San Antonio, Texas

  • Alliance for Multispecialty Research, LLC ( Site 0092)

    Kaysville, Utah

  • Wee Care Pediatrics ( Site 0077)

    Layton, Utah

Showing 40 of 217 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.